Cellectar Biosciences Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
CLRB$1.28+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements
FINANCIAL STATEMENTS
INDEX TO FINANCIAL STATEMENTS FOR CELLECTAR BIOSCIENCES, INC.
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (Deloitte & Touche LLP, Morristown, New Jersey, PCAOB ID No. 34) | 61 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | 63 |
| Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023 | 64 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years Ended December 31, 2024 and 2023 | 65 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | 66 |
| Notes to Consolidated Financial Statements | 67 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.